Depomed Inc. (NASDAQ:DEPO) CFO August J. Moretti sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $20.84, for a total value of $104,200.00. Following the completion of the transaction, the chief financial officer now directly owns 26,680 shares of the company’s stock, valued at $556,011.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Depomed Inc. (NASDAQ:DEPO) opened at 20.55 on Friday. The company’s market cap is $1.27 billion. Depomed Inc. has a 1-year low of $12.25 and a 1-year high of $27.02. The company has a 50-day moving average price of $23.17 and a 200-day moving average price of $20.91.

Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Monday, November 7th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.35 by $0.07. The business had revenue of $111 million for the quarter, compared to analysts’ expectations of $127.22 million. Depomed had a negative return on equity of 7.49% and a negative net margin of 16.93%. The company’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS. On average, analysts expect that Depomed Inc. will post $1.04 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Several hedge funds and other institutional investors have recently modified their holdings of DEPO. Oxford Asset Management boosted its position in shares of Depomed by 6.1% in the second quarter. Oxford Asset Management now owns 1,209,180 shares of the specialty pharmaceutical company’s stock valued at $23,724,000 after buying an additional 69,280 shares in the last quarter. First Manhattan Co. boosted its position in Depomed by 16,250.0% in the second quarter. First Manhattan Co. now owns 327,000 shares of the specialty pharmaceutical company’s stock worth $6,415,000 after buying an additional 325,000 shares during the period. PineBridge Investments L.P. boosted its position in Depomed by 4.1% in the second quarter. PineBridge Investments L.P. now owns 7,748 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 306 shares during the period. BNP Paribas Arbitrage SA boosted its position in Depomed by 620.1% in the second quarter. BNP Paribas Arbitrage SA now owns 20,156 shares of the specialty pharmaceutical company’s stock worth $395,000 after buying an additional 17,357 shares during the period. Finally, ClariVest Asset Management LLC boosted its position in Depomed by 15.5% in the second quarter. ClariVest Asset Management LLC now owns 92,487 shares of the specialty pharmaceutical company’s stock worth $1,814,000 after buying an additional 12,400 shares during the period.

Several equities analysts recently commented on DEPO shares. Mizuho reiterated a “positive” rating on shares of Depomed in a research note on Thursday, July 21st. Piper Jaffray Cos. downgraded Depomed from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $21.00 to $18.00 in a research note on Wednesday, July 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $26.00 price objective on shares of Depomed in a research note on Thursday, July 28th. Janney Montgomery Scott restated a “buy” rating and set a $28.00 target price on shares of Depomed in a research report on Thursday, August 4th. Finally, JMP Securities dropped their target price on Depomed from $28.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 4th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. Depomed currently has an average rating of “Hold” and a consensus price target of $23.06.

About Depomed

5 Day Chart for NASDAQ:DEPO

Receive News & Stock Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related stocks with our FREE daily email newsletter.